Table 5.
R0 resection rate of gastric cancer in patients after neoadjuvant chemotherapy and surgery versus upfront surgery
Ref.
|
R0 resection rate
|
P value
|
|
NAT
|
US
|
||
Ahn et al[8], 2014 | 92.2% | ||
Biondi et al[9], 2018 | 82.9% | 83.6% | 0.449 |
Bracale et al[10], 2021 | NS | NS | |
Eom et al[11], 2018 | 97.7% | 97.7% | |
Feng et al[12], 2015 | 95% | 94.4% | |
Wang et al[13], 2021 | 84.6% | 56.7% | 0.029 |
Xue et al[14], 2018 | 100% | 96% | |
Kang et al[15], 2021 | NS | NS | |
Kano et al[16], 2019 | 100% | 100% | |
Lin et al[17], 2022 | 90.1% | ||
Marino et al[18], 2021 | NS | NS | |
Molina et al[19], 2013 | - | 80% | |
Pardo et al[20], 2020 | NS | NS | |
Wang et al[21], 2019 | 89.2% | 84.6% | > 0.05 |
Wang et al[22], 2021 | 96%1 | 89%1 | 0.061 |
Wu et al[23], 2019 | NS | NS | |
Xu et al[24], 2021 | 94.12% | 89.14% | 0.072 |
Zhao et al[25], 2017 | NS | NS |
Neoadjuvant chemoratdiotherapy versus neoadjuvant chemotherapy (96% vs 89%, P = 0.06).
NAT: Neoadjuvant chemotherapy; US: Upfront surgery; NS: Not stated.